Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors

A compound of the Formula (I) or pharmaceutically acceptable salts thereof:

• wherein:
• is a single bond or a double bond;
• X and Y are each independently selected from C or N;
• X and Y are N, wherein R5 and R7 are absent;
• R1 and R2 are each independently selected from H, alkyl, cycloalkyl, heterocyclo alkyl, aryl, heteroaryl, alkoxyl, aryoxyl, —COOR9, —CONR9R10, —C(═S)NR9R10, —CORS, —SOR9, —SO2R9, —SO2NR9R10 and —P(═O)(OR9)(OR10);
• R3 is selected from alkyl, trifluoromethyl, aryl and aralkyl, wherein said alkyl, aryl or aralkyl is substituted by one more halogen and hydroxy;
• R4 is selected from alkyl, cycloalkyl, heterocyclo alkyl, aryl, heteroaryl, heteroaryl, alkenyl, alkynyl, —(CH2)n(OCH2CH2)rR11, —[CH2CH(OH)]rCH2NR9R10 and —(CH2)nNR9R10, wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclo alkyl is optionally substituted by one more groups selected from the group consisting of aryl, hydroxyl, amino, amide group, aminocarbonyl, alkoxyl, aryoxyl, aminoalkyl, hydroxyalkyl, heterocyclo alkyl, carboxylic acid, carboxylic ester and —NR9R10;
• X and Y are C, wherein R5, R6, R7, R8 are each independently selected from hydrogen, halo, haloalkoxyl, alkyl, cycloalkyl, heterocyclo alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, —OR9, —O[CH2CH2O]rR11, —SR9, —NR9R10, —SOR9, —SO2R9, —NSO2R9, —SO2NR9R10, —(CH2)nCO2R9, —(CH2)nCONR9R10, —C(═S)NR9R10, —CORS, —NR9COR10, —NHCO2R10, —OCO2R9, —OCO2NR9R10, —CN and —NO2, wherein said aryl, heteroaryl, cycloalkyl, heterocyclo alkyl are substituted by one more groups consisting of alkyl, alkoxyl and halogen;
• R9 and R10 are each independently selected from hydrogen, alkyl, cycloalkyl, heteroaryl and heterocyclo alkyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclo alkyl are each independently substituted by one more groups consisting of alkyl, aryl, hydroxyl, amino, amide group, aminocarbonyl, cyano, alkoxyl, aryoxyl, aminoalkyl, hydroxyalkyl, heterocyclo alkyl, carboxylic acid and carboxylic ester;
• R9 and R10 are taken together with the atom to which they are attached to form 4 to 8 membered rings, wherein the 5 to 8 membered rings may further optionally contain one to three heteroatoms selected from the group consisting of N, O and S, and the 4 to 8 membered rings so formed are each optionally substituted by one more groups consisting of alkyl, aryl, heteroaryl, haloalkyl, haloalkoxyl, hydroxyl, amino, amide group, cyano, alkoxyl, aryoxyl, aminoalkyl, hydroxyalkyl, heterocyclo alkyl, carboxylic acid, carboxylic ester, halogen and —NR9R10,
• R11 is hydrogen or alkyl;
• n is 2-6;
• and
• r is 1-6.